Surfing-inspired saltwater mist gives relief from cystic fibrosis

May 2013
Engineer (Online Edition);5/30/2013, p6
The article discusses the development of the trans-nasal pulmonary aerosol delivery (tPAD) device by Parion Sciences and Cambridge Consultants, which can be used overnight by cystic fibrosis (CF) patients. The aerosol nebulizer was inspired by scientists' observations regarding the therapeutic benefits derived by surfers with CF when they inhaled seawater mist. Rehydrating the layer of mucus film lining the lungs of CF patients by inhaling a hypertonic saltwater solution is cited.


Related Articles

  • TOBI Podhaler Approved.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, pA-26 

    The article informs that the tobramycin inhalation powder TOBI Podhaler from Novartis AG has been approved for treatment of cystic fibrosis in patients with Pseudomonas aeruginosa in lungs.

  • Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device. Elkins, Mark R.; Anderson, Sandra D.; Perry, Clare P.; Daviskas, Evangelia; Charlton, Brett // Open Respiratory Medicine Journal;2014, Vol. 8, p8 

    Introduction: Drug inhalation via a dry-powder inhaler (DPI) is a convenient, time efficient alternative to nebulizers in the treatment of cystic fibrosis (CF) or non-CF bronchiectasis. Efficient drug administration via DPIs depends on the device resistance and adequate (⩾45L/min)...

  • Gilead Widens CF Pipeline In $156M Deal With Parion. Morrison, Trista // BioWorld Today;8/17/2007, Vol. 18 Issue 160, p1 

    The article reports on the addition of the cystic fibrosis drug, epithelium sodium channel inhibitor P-680 from Parion Sciences Inc. to the pharmaceutical line of Gilead Sciences Inc. The licensing of P-680 will cost Gilead $156 million including the licensing fee, equity purchase and funding...

  • Risk of Colobreathe capsule breakage.  // Reactions Weekly;Dec2014, Vol. 1532 Issue 1, p8 

    The article presents a medical findings on the risk of breakage of colistimethate sodium (Colobreathe) gelatin capsules when they are pierced by an inhalation device.

  • Development of Dry Powder Inhalers. Chougule, Mahavir B.; Padhi, Bijay K.; Jinturkar, Kaustubh A.; Misra, Ambikanandan // Recent Patents on Drug Delivery & Formulation;Jan2007, Vol. 1 Issue 1, p11 

    Development of dry powder inhalers involves powder recrystallization, formulation, dispersion, delivery, and deposition of the therapeutic agent in different regions of the airways in prophylaxis/ treatment/ diagnosis of pulmonary and systemic disorders. Conventional powder production by...

  • Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients. van Koningsbruggen-Rietschel, S.; Heuer, H. E.; Merkel, N.; Posselt, H. G.; Staab, D.; Sieder, C.; Ziegler, J.; Krippner, F.; Rietschel, E. // Journal of Antimicrobial Chemotherapy (JAC);Mar2016, Vol. 71 Issue 3, p711 

    Objectives: We evaluated the pharmacokinetics, safety and tolerability of two different continuous treatment regimens of tobramycin inhalation solution (TIS) in 29 cystic fibrosis (CF) patients chronically infected with Pseudomonas aeruginosa.Patients and Methods: In...

  • Wireless Control for Medical Device.  // Appliance Design;Oct2006, Vol. 54 Issue 10, p8 

    This article reports on a prototype device developed by Great Britain-based Cambridge Consultants which uses Near Field Communication technology from the Netherlands-based Philips Electronics to wirelessly link glucometers and insulin pumps. The blood sugar is recorded by the glucometer, which...

  • Deals roundup.  // Medical Device Daily;12/11/2008, Vol. 12 Issue 220, p3 

    The article reports on the signing of an exclusive technology license and purchase agreement of 3M Drug Delivery Systems with Cambridge Consultants for its Conix Dry Powder Inhaler (DPI) technology platform. According to James Vaughan, division vice president of 3M Drug Delivery Systems...

  • The future of drug delivery. Pavlou, Fedra; Lawrence, Corrine; Sutton, Stephanie // Pharmaceutical Technology Europe;Jan2010, Vol. 22 Issue 1, p20 

    An interview with Andrew Diston, head of global medical technology practice at Cambridge Consultants Inc. is presented. When asked on alteration of the drug delivery device sector, he says that the loss of revenue from patent-protected drugs gave rise to a market for generic drugs. Diston...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics